Resistance to chemotherapy is believed to be a major cause of treatment failure in pancreatic cancer. Thus, it is necessary to explore alternative therapeutic modalities to overcome drug resistance in pancreatic cancer treatment. We tested the hypothesis that Src tyrosine kinase inhibition could augment the chemosensitivity of 5-fluorouracil (5-FU)-resistant human pancreatic cancer cells to 5-FU. As detected by MTT proliferation assay, propidium iodide and annexin V staining, a combination of 5-FU þ Src kinase inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo [3,4-d]pyrimidine) reflected the chemotherapeutic sensitivity and restored the 5-FU-induced apoptosis in 5-FU-resistant cells. Furthermore, when small-interfering RNA approach to silence Src gene expression was applied, the degree of 5-FU-induced apoptosis was increased in all cell lines independently of the chemoresistance status. Western blotting and RT-PCR analysis revealed that the expression of thymidylate synthase (TS) was higher in 5-FU-resistant cells, however, decreased significantly after pretreatment with PP2. Furthermore, the combination of 5-FU þ PP2 decreased the 5-FU-induced activation of epidermal growth factor receptor (EGFR)-AKT pathway. Finally, PP2 in combination with 5-FU substantially decreased the in vivo tumor growth and inhibited distant metastases. Taken together, 5-FU chemoresistance can be reversed through indirect TS regulation by inhibiting Src tyrosine kinase. A potential mechanism of action of Src kinase inhibitors on 5-FU chemosensitivity might be linked to the inhibition of 5-FU-induced EGFR-AKT activation.
Introduction
Five-fluorouracil (5-FU) is widely used in the treatment of solid gastrointestinal tumors, including pancreatic cancer (Kollmannsberger et al., 1996; Blaszkowsky, 1998) . 5-FU inhibits cancer cell growth and initiates apoptosis by targeting thymidylate synthase (TS) and by direct incorporation of 5-FU metabolites into DNA and RNA (Pinedo and Peters, 1988; Chu et al., 2003) . 5-FU can also induce DNA and RNA strand breaks and apoptosis by direct incorporation of fluorinated nucleotides into DNA and RNA (Major et al., 1982; Lo¨nn and Lo¨nn, 1984; Goshal and Jacob, 1997) . Despite the understanding of the mechanism of action of 5-FU, the development of 5-FU-resistant cancer phenotypes remains a significant limitation to its use. 5-FU sensitivity and patient's survival are inversely related to the level of TS protein and enzyme activity in cancer cells, and 5-FU-resistant tumors commonly express high levels of TS protein (Beck et al., 1994; Johnston et al., 1995; Wang et al., 2001; Peters et al., 2002; Popat et al., 2004) .
Multiple mutations and changes in the expression of proto-oncogenes occur at a very high frequency in pancreatic cancer (Crnogorac-Jurcevic et al., 2001; Moore et al., 2001) . Various oncogenes in signaling pathways have been indicated to contribute to drug resistance, including ras, protein kinase C, src, and so on (Masumoto and Nakano, 1997) . The src oncogene is not only an archetype of the cytoplasmic signaling connectors but also one of the most commonly activated oncogenes that is associated with tumorigenesis of approximately 70% of human pancreatic cancers (Lutz et al., 1998; Summy and Gallick, 2003; Paul and Mukhopadhyay 2004; Yezhelyev et al., 2004; Summy et al., 2005; Kleespies et al., 2006) . Although inhibitors of the tyrosine kinase Src, such as 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2) or AZM475271, have been found to interact synergistically with 5-FU in our preclinical in vivo model of pancreatic cancer (unpublished data), data suggesting that such strategy can overcome acquired 5-FU resistance are limited to date.
For these reasons, the aim of study has been to focus on Src kinase inhibitors not only as anti-tumor agents but also as agents potentially capable of circumventing acquired pancreatic tumor cell resistance to 5-FU. Using 5-FU-resistant pancreatic cancer cell lines, we assessed the effect of suppressing Src activity on pancreatic cancer chemoresistance and apoptosis.
Results
In vitro selection of the 5-FU-resistant pancreatic cancer cells AsPC 5-FU RES and L3.6pl 5-FU RES As detected by the MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) proliferation assay, after the period of over 1 year of repetitive exposure to 5-FU, both cell lines demonstrate a permanent acquired chemoresistance. The sensitivity of AsPC 5-FU RES cells to 5-FU was significantly decreased, reaching an IC 50 that was almost threefold higher than that of the parental cell line. Similar to the sensitivity of AsPC 5-FU RES cells, the sensitivity of L3.6pl 5-FU RES cells to 5-FU was also diminished (a fivefold difference) (Table 1) . Furthermore, the stability of resistant phenotype in the absence of 5-FU was examined in both AsPC 5-FU RES and L3.6pl 5-FU RES cells. When the cells were passaged without 5-FU for 4 weeks, the 5-FU IC 50 remained stable (data not shown).
Exposure to 5-FU does not universally protect pancreatic cancer cells from all chemotherapeutic agents
To determine whether 5-FU-resistant cells were resistant to other chemotherapeutic agents, we evaluated the IC 50 for some other chemotherapeutic drugs widely used in the clinic for the treatment of pancreatic cancer, such as gemcitabine and irinotecan hydrochloride. Interestingly, both 5-FU-resistant cell lines remained sensitive to these agents (Table 2) . Thus, resistance of AsPC 5-FU RES and L3.6pl 5-FU RES seemed to be specific to 5-FU. Furthermore, taken together, our findings indicate that the significant acquired resistance of these cell lines toward 5-FU is not associated with a multidrug-resistance phenotype of both cell lines.
Inhibition of Src tyrosine kinase activity by PP2 enhances 5-FU-induced cytotoxicity As reported in previous studies, treatment with Src kinase inhibitor PP2 reduced proliferation of human liver, colon and breast cancer cell lines (Nam et al., 2002) . It was most important for our further cytotoxicity assays to apply a concentration of PP2 that would rather be associated with the direct Src inhibitory properties of drug than with a nonspecific intracellular drug targeting. At 10 mM, PP2 had no significant effect on cellular proliferation, indicating that at such a low concentration, the effect of PP2 on 5-FU cytotoxicity might not simply reflect a direct anti-proliferative effect, but rather a potentiation of 5-FU-induced cytotoxicity (data not shown). As shown in Figure 1 , treatment with PP2 significantly reduced the 5-FU IC 50 for AsPC-1 and L3.6pl cell lines (with the 5-FU IC 50 decreasing 4-fold for AsPC-1 and 10-fold for L3.6pl, respectively). Most interestingly, the inhibition of Src kinase by PP2 reversed acquired 5-FU resistance in both chemotherapy-resistant cell lines. After exposure to PP2, the mean 5-FU IC 50 for AsPC 5-FU RES or for L3.6pl 5-FU RES nearly reached the mean 5-FU IC 50 of their corresponding parental cell lines (Figure 1 ).
Inhibition of Src tyrosine kinase activity by PP2 induces apoptosis in 5-FU-resistant cells after 5-FU treatment To further investigate the underlying mechanism for the observed reduction in cell growth, we determined the 5-FU-induced apoptosis in 5-FU-resistant cells and evaluated whether PP2 could increase cell apoptosis induced by 5-FU. As detected by flow cytometry using propidium iodide staining, treatment with 5-FU caused a significant increase in cell apoptosis in both AsPC-1 and L3.6pl cells. Furthermore, PP2 in combination with 5-FU demonstrated a clear synergistic effect in these cell lines (Figures 2a and b) . By contrast, when chemotherapy-resistant cells were treated with the corresponding 5-FU IC 50 , the proportion of cells undergoing apoptosis was significantly lower; however, the presence of PP2 substantially restored the apoptotic response toward 5-FU (Figures 2c and d) . Furthermore, using Annexin V staining, we studied whether PP2-enhanced 5-FU efficacy might have been the result of early proapoptotic effects of combined therapy. As shown in Figure 2e , the percentage of the cell population undergoing early apoptosis was significantly greater in both chemotherapy-resistant and sensitive cells after the PP2 þ 5-FU combination therapy.
Src specifically regulates 5-FU chemosensitivity in both parental and chemotherapy-resistant cell lines For a definitive answer with respect to the role of Src in 5-FU chemoresistance, an RNAi approach to silence Src was applied. As seen in Figure 3a , cells expressing the (Figure 4a) . The total amount of TS protein (free TS and ternary complex) increased significantly in all cell lines independent of their status of resistance. The transient induction of TS might be ascribed to a feedback regulation in the synthesis of TS by binding of the excess TS to its own mRNA (the phenomenon called 'acute resistance to 5-FU') (Chu et al., 1990; Chu and Allegra 1996) .
Furthermore, TS mRNA expression was assessed by RT-PCR. As shown in Figure 5 , considerable changes in TS mRNA expression were observed in chemotherapy-resistant cells. The expression of TS gene on transcription level was significantly higher in both cell lines than that in their parental cell lines. Prominently, TS mRNA was markedly suppressed by 5-FU in parental AsPC-1 and L3.6pl cells; however, no significant alteration of TS mRNA expression was observed in chemotherapy-resistant cells ( Figure 5 ).
Overexpression of TS is suppressed by PP2 in chemotherapy-resistant cell lines On the basis of our results, we next hypothesized that the chemo-sensitizing effect of Src kinase inhibition might be associated with an indirect upregulation of 5-FU-resistance-associated TS, which in turn limits 5-FU efficacy. As shown in Figure 4a , the overexpression of TS protein in chemotherapy-resistant cells was significantly inhibited by the presence of PP2. Moreover, the ternary complex of TS with FdUMP and CH 2 -THF was mostly non-detectable. To exclude an Src-independent direct interaction of PP2 and TS, we repeated the same experiments with a second Src kinase inhibitor AZM475271. Taken together, AZM475271 when applied as chemo-sensitizer induced the similar changes in TS protein expression (Figure 4a ).
In a next step, we analyzed the relative expression of TS mRNA in response to PP2 treatment. Interestingly, PP2 demonstrated a slight but not statistically significant downregulation of TS mRNA expression in parental cells. However, the elevated expression of TS mRNA in chemotherapy-resistant cells was suppressed when PP2 was implicated as chemo-sensitizer ( Figure 5 ).
Expression of dihydropyrimidine dehydrogenase does not correlate with the acquired resistance to 5-FU Most studies of advanced cancer have reported worse prognoses and decreased responses to 5-FU chemotherapy with higher levels of dihydropyrimidine dehydrogenase (DYPD) expression (Salonga et al., 2000) . 
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Hence, in addition to the analysis of TS expression, we evaluated the expression of DYPD in AsPC-1 and L3.6pl cell lines, both sensitive and resistant. Interestingly, no clear relationship was found between DYPD expression and 5-FU sensitivity. Furthermore, pretreatment of all cell lines with PP2 had no effect on the DYPD intracellular expression (Figure 4b ).
5-FU-induced EGFR-AKT pathway activation is affected by PP2 in chemotherapy-resistant cell lines
At present, it is widely accepted that epidermal growth factor receptor (EGFR) promotes cell proliferation and survival through the activation of the extracellular signal-regulated kinase (ERK) or the AKT pathway. Furthermore, EGFR activation induced by chemotherapy may have a significant function in survival response Reverse of 5-FU chemoresistance by targeting Src tyrosine kinase I Ischenko et al against apoptosis (Miyazaki et al., 2001; Van Schaeybroeck et al., 2005) . With the aim to elucidate the mechanisms involved in regulating the interaction between 5-FU and PP2, we first examined the effect of exposure of 5-FU on EGFR phosphorylation in the absence of ligand stimulation. Interestingly, 5-FUinduced phosphorylation of EGFR was found in AsPC-1 and L3.6pl cell lines, both sensitive and resistant (Figure 6a ).
To further examine the signaling pathways required for Src-mediated 5-FU chemosensitivity, we analyzed the expression and activity of Src kinase following epidermal growth factor (EGF) stimulation in AsPC-1 and L3.6pl cells, both sensitive and resistant. As shown in Figure 6b , an increased phosphorylation of Src kinase after 5-FU therapy was observed in both AsPC-1 and AsPC 5-FU RES cells. The same analysis was performed in L3.6pl cells expressing higher levels of Src protein than that in AsPC-1 cells. Interestingly, in the absence of 5-FU, increased phosphorylation of Src kinase was observed in L3.6pl 5-FU RES as compared with sensitive L3.6pl cells (Figure 6c) . Thus, the increased activity of Src kinase in chemotherapy-resistant cell lines was a result of either 5-FU-induced EGFR-Src pathway activation or constitutive steady-state autophosphorylation. To further investigate the EGFR-Src downstream signaling in AsPC-1 and L3.6pl cells, we examined the effects of 5-FU and PP2 on the final steps of EGFR signaling, p44/p42 (activated mitogen-activated protein (MAP) kinase) and AKT (phosphoinositide 3-kinase pathway). Interestingly, the AKT protein was more constitutively active in AsPC 5-FU RES than in AsPC-1 cells (Figure 6b) . Furthermore, treatment with 5-FU of both AsPC-1 and AsPC 5-FU RES cells led to a significant induction in the AKT phosphorylation under the presence of EGF. Most importantly, a combination of 5-FU þ PP2 decreased 5-FU-induced AKT activation in these cells (Figure 6b ). The impact of 5-FU þ PP2 on AKT phosphorylation in L3.6pl and L3.6pl 5-FU RES cells was comparable with that observed in AsPC-1 and AsPC 5-FU RES cells (Figure 6c) .
In contrast, treatment with 5-FU did not induce marked changes in MAP kinase phosphorylation in AsPC and L3.6pl cells (both sensitive and resistant), and the combination of 5-FU þ PP2 did not generally affect the EGF-induced p44/p42 activation (Figures 6b and c) .
PP2 restores chemosensitivity of AsPC 5-FU RES pancreatic tumors toward 5-FU in vivo The ability of PP2 being applicable as the chemosensitizer for 5-FU was further analyzed in vivo. The design of experiment is reflected in Figure 7a . As shown in Figure 7b , 5-FU alone had no significant effect on tumor progression, and the Src kinase inhibitor PP2 caused a slight but not significant reduction in tumor growth. In contrast, the combination of PP2 and 5-FU restored the chemotherapeutic sensitivity of 5-FU-resistant pancreatic tumors toward 5-FU. On killing, the combination of PP2 and 5-FU produced a marked inhibition of AsPC 5-FU RES tumor growth (Figure 7c) . Furthermore, when administered in combination, 5-FU and PP2 resulted in no detectable liver and distant lymph node metastases (Table 3) .
Discussion
The major obstacle in cancer chemotherapy is the phenomenon of acquired chemoresistance, where tumor cells become refractory to drug treatment. In pancreatic cancer, acquired chemoresistance is a major problem, notably in therapy with 5-FU and gemcitabine, which are widely used in the treatment of disease. Attempts to modulate 5-FU cytotoxicity have been focused primarily on enhancing TS inhibition (5-FU þ leucovorin, 5-FU þ methotrexate) (DeCaprio et al., 1991), but until now, relatively little was known regarding a specific role of Src kinase inhibitors as therapeutic agents being potentially capable of circumventing acquired pancreatic tumor cell resistance to 5-FU.
In our study, treatment of 5-FU-resistant pancreatic cancer cells with the Src kinase inhibitor PP2 enhanced 5-FU-induced cytotoxicity, promoted 5-FU-induced apoptosis and finally restored chemotherapy resistance in vitro and in vivo. For a definitive answer with respect to the role of Src in 5-FU chemoresistance, an RNAi approach to silence Src was applied. Taken together, the results from RNAi approach were consistent with those obtained by pharmacologic inhibition of Src kinase and indicated that Src was required for the chemo-sensitizing effect observed in chemotherapy-resistant cells.
We further attempted to elucidate the underlying mechanism responsible for the chemo-sensitizing effect of PP2 noted in vitro and in vivo by studying the expression of TS and DYPD as the main modes of action of 5-FU. When compared with the parental AsPC-1 and L3.6pl cells with low TS protein, high expression of TS protein and mRNA levels was detected in both 5-FU-resistant cell lines. Most interestingly, treatment with PP2 or AZM475271, followed by therapy with 5-FU, led to a significant inhibition of TS protein expression in AsPC-1 and L3.6pl cells, both sensitive and resistant. Furthermore, pretreatment with Reverse of 5-FU chemoresistance by targeting Src tyrosine kinase I Ischenko et al PP2 modulated 5-FU-associated ternary complex of TS with FdUMP and CH 2 -THF: the ternary complex was mostly non-detectable. Interestingly, in our investigation, no clear correlation was found between DYPD expression and the response to 5-FU in both AsPC 5-FU RES and L3.6pl 5-FU RES cells. Therefore, we suggest that TS expression is only one factor that can predict 5-FU sensitivity in 5-FU-resistant cells developed in our laboratory. There have also been a few reports, in which the 5-FU-targeted TS enzyme and DYPD, the rate-limiting enzyme, have been considered as independent factors (Hamaji et al., 2002) . Furthermore, some cases demonstrated low 5-FU sensitivity despite having low DYPD activity, so it is not clear whether DYPD activity could predict response to 5-FU treatment.
The interaction between PP2 and 5-FU underlying the observed chemotherapeutical potentiation is most likely downstream of the sites of specific pharmacological Reverse of 5-FU chemoresistance by targeting Src tyrosine kinase I Ischenko et al effect of PP2 and more globally determinates at the level of intracellular growth control and apoptosis signaling. In this respect, Src kinase inhibitory drugs might be similar in their ability to potentiate the action of various cytotoxic agents with different mechanisms of action. In view of the above, it is of interest to note that PP2 has been shown to augment gemcitabine-induced caspasemediated apoptosis, to suppress RRM2 expression (a putative chemoresistance enzyme) and to decrease activity of the RRM2-regulating transcription factor E2F1 in gemcitabine-resistant pancreatic carcinoma cell line PANC-1 (Duxbury et al., 2004) . Zhao et al. (2006) found that the 5-FU-chemoresistant sublines of pancreatic carcinoma cells had higher resistance to apoptosis correlating with the resistance index. Compared with parental cells, the activity of the ERK was elevated in all of the three chemoresistant sublines at basal conditions. Inhibition of the ERK pathway by PD98059 sensitized cells to 5-FU. In addition, the study also provided evidence for a possible link between the ERK pathway and activation of caspases (5-FU induced apoptosis primarily through a caspase-8-dependent pathway) and Bcl-2. These findings are consistent with other reports showing that resistance to apoptosis is a main contributor to 5-FU chemoresistance (Wu et al., 1998; Igney and Krammer, 2002) . Recent studies demonstrated Src kinase as a transductor in regulation of the above-described ERK survival pathway. There is some circumstantial evidence that the activation of the ERK mitogenic pathway could also be important for downstream signaling pathways of Src during cell survival (Thomas and Brugge, 1997; Frame, 2002) . However, we were not able to demonstrate any changes in the EGFR-ERK pathway after 5-FU or PP2 treatment in the present investigation. Such absence of relationship may be considered as a tumor-type or celltype-dependent interaction.
We further examined the effect of exposure of 5-FU on EGFR phosphorylation in the absence of ligand stimulation. Increased EGFR phosphorylation in cancer cells following exposure to cytotoxic drugs has been shown in other studies (Koizumi et al., 2004) , and the activation of EGFR could constitute a pro-survival response. Furthermore, a number of reports have suggested that EGFR promotes cell survival and protects cells from death-receptor-mediated apoptosis through the activation of AKT pathway (Gibson et al., 1999) . Our results suggest that the nature of the synergistic interaction between PP2 and 5-FU and the observed chemo-sensitizing effect is most likely associated with the inhibition of EGFR-AKT intracellular pathway by PP2.
We further speculate that Src might regulate the response of 5-FU-resistant pancreatic cancer cells Reverse of 5-FU chemoresistance by targeting Src tyrosine kinase I Ischenko et al to 5-FU in different pancreatic cancer cell lines and revealed that the acquired 5-FU resistance might at least partially be mediated by upregulation of the inhibitors of apoptosis bcl-x L and mcl-1; furthermore, the ratio of bax/bcl-2 was predictive for sensitivity toward 5-FU. Mitochondrial apoptosis pathways are mostly regulated by pro-and anti-apoptotic members of the Bcl-2 protein family, and Src is either directly or indirectly involved in the regulation of the activity of Bcl-2 proteins (Karni et al., 1999) . Alternatively, Src may additionally modulate the apoptotic threshold for 5-FU-induced apoptosis by interfering with upstream signaling molecules involved in apoptosis regulation. Previous studies revealed that Src participates in the phosphoregulation of phosphatidylinositol-3-kinase, AKT, GTPases of the Rho-family or nuclear factor-kB (NF-kB), all being involved in the control of proliferation and/or apoptotic cell death (Thomas and Brugge, 1997; Frame, 2002) . In fact, 5-FU was described to induce activation of NF-kB in two colon cancer cell lines and four out of five TS inhibitor-resistant colon cancer cell lines were found to overexpress NF-kB mRNA and protein levels . Moreover, Voboril et al. (2004) recently demonstrated that the inhibition of NF-kB enhanced the cytotoxic effect of 5-FU also in colon cancer cells. The chemo-sensitizing effect of Src kinase inhibition might also be associated with other 5-FU-resistance-associated enzymes, such as thymidine phosphorylase or orotate phosphoribosyl transferase.
Finally, the existence of human cancer stem cells displaying increased radiotherapy and chemotherapy resistance has recently been proven (Collins et al., 2005; Szotek et al., 2006; Hermann et al., 2007; O'Brien et al., 2007) . The discovery of an increased population of such cells in 5-FU-resistant pancreatic cancer may further underline the nature of pancreatic cancer chemoresistance (data not shown).
In summary, 5-FU efficacy has been shown to be reversed by indirect TS upregulation by inhibiting Src tyrosine kinase. As we detected no therapy-associated toxicity, such as diarrhea or loss of body weight, in the 5-FU þ PP2 combination group in vivo, long-term administration of Src kinase inhibitor at sub-therapeutic doses (with the aim to potentially chemosensitize 5-FUresistant tumors toward 5-FU) may be a promising strategy in the treatment of pancreatic cancers, at least those displaying resistance to 5-FU.
Materials and methods

Cell culture and chemicals
We chose the well-known human pancreatic adenocarcinoma cell lines AsPC-1 and L3.6pl as the parental cell lines from which to develop the 5-FU-resistant cell lines to study the mechanisms of 5-FU resistance. The cells were subcultured in medium with increasing concentrations of 5-FU, starting at the IC 50 , for 3 days, followed by recovery periods in drug-free medium until the cells regained exponential growth. All cell lines were maintained in Dulbecco's minimal essential medium (D-MEM; Invitrogen GmbH, Karlsruhe, Germany), supplemented with 10% fetal bovine serum (Biochrom AG, Berlin, Germany).
5-FU was purchased from GRY-Pharma (GRY-Pharma GmbH, Kirchzarten, Germany), gemcitabine (GEMZAR) and irinotecan (CAMPTO) hydrochloride were obtained from Lilly Deutschland GmbH (Bad Homburg, Germany) and Pfizer GmbH (Karlsruhe, Germany), respectively. We used two different highly specific Src tyrosine kinase inhibitors, namely AZM475271 donated by AstraZeneca Pharmaceuticals (Macclesfield, UK) and 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2; Calbiochem, San Diego, CA, USA). For in vitro applications, the AZM475271 and PP2 stocks were prepared in dimethyl sulfoxide, and the chosen concentrations of both compounds did not inhibit other intracellular kinases without any effect on cell proliferation (data not shown).
Chemosensitivity assay
We used an in vitro TACS MTT Cell Proliferation and Viability Assay Kit (R&D Systems, Minneapolis, MN, USA). Cells were cultured at 15 Â 10 3 cells per well in 96-well tissue culture plates. To assess cell viability, stepwise 10-fold dilutions of 5-FU were added 24 h after plating, and the cultures were incubated at 37 1C for 72 h. At the end of the culture period, cells were washed with phosphate-buffered saline, the MTT reagents were added according to the manufacturer's recommendations and the absorbance was measured at 570 nm using an ELISA plate reader. Mean values were calculated from three independent experiments. Chemosensitivity is expressed here as the drug concentration for 50% cell survival (IC 50 ). The same methodology was used to determine the IC 50 for gemcitabine and irinotecan hydrochloride. To investigate the chemo-sensitizing effect of Src kinase inhibitors, 5-FU was applied to cell culture following therapy with the Src kinase inhibitor PP2. This study involved the 24 h pretreatment with PP2, which was then removed and cells were treated for the subsequent 24 h with 5-FU alone.
Determination of apoptotic cells by FACS analysis by propidium iodide and Annexin V staining Non-confluent AsPC-1, L3.6pl and their appropriate 5-FUresistant cell lines were incubated either with the corresponding 5-FU IC 50 for 24 h or PP2 10 mM for 24 h or with 5-FU in combination with PP2. After therapy, cells were collected and suspended in Nicoletti buffer (0.1% sodium citrate, pH 7.4, 0.1% Triton X-100 and 50 mg/ml propidium iodide). DNA content present in the resulting nuclei was determined on a fluorescence-activated cell sorter (FACS; Becton Dickinson GmbH, Heidelberg, Germany). The cells undergoing early apoptosis were determined using an Annexin V-FITC Apoptosis Detection Kit II (BD Biosciences, Heidelberg, Germany) according to the manufacturer's instructions. Experiments were repeated three times.
Analysis of protein expression by western blotting
Non-confluent cells were treated or not in serum-reduced D-MEM. Following chemotherapy, the cells were stimulated with 50 ng/ml human EGF (Sigma-Aldrich Chemie GmbH, Munich, Germany) for 10 min, washed with ice-cold phosphate-buffered saline and resuspended in ice-cold RIPA buffer supplemented with the cocktail of protease/phosphotase inhibitors (Roche, Mannheim, Germany) to a final concentration of about 10 7 -10 8 cells per millilter. An equal amount of protein was run on polyacrylamide gels, transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA) and detected using an enhanced chemiluminescense system (Amersham, Braunschweig, Germany). Phosphorylated EGFR and total EGFR, phosphorylated Src and total Src, phosphorylated AKT and total AKT, phosphorylated extracellular signal-regulated kinase (MAPK) and total MAPK antibodies were purchased from Cell Signaling (New England Biolabs, Frankfurt am Main, Germany). Anti-b-actin antibody was purchased from Sigma (Sigma-Aldrich Chemie GmbH, Munich, Germany). All antibodies were used according to the manufacturer's instructions.
For the analysis of TS or DYPD protein expressions, the cells were treated or not, washed with ice-cold phosphatebuffered saline and whole extracts were prepared using RIPA buffer as described above. The antibodies against TS and DYPD were purchased from Chemicon International (Millipore GmbH, Schwalbach, Germany) and Santa Cruz Biotechnology (Heidelberg, Germany), respectively, and used according to the manufacturer's instructions.
Analysis of TS gene expression by RT-PCR
Total RNA from cultured cells was isolated using the RNAeasy Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. Reaction of 0.1 mg total RNA was performed using a SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity Kit (Invitrogen GmbH). The primer sequences used were as follows: TS low (GCAGGGCGTAGCTGGCGATGTTGAAAG); TS up (CT GGAAGGGTGTTTTGGAGGAGTTGCTGTGG); GAPDH low (GACGCCTGCTTCACCACCTTCTTGATGTC); GAP DH up (GAGTCAACGGATTTGGTCGTATTGGGCG); b-actin low (CTCGCGGTTGGCCTTGGGGTTCAG); b-actin up (GATGATGATATCGCCGCGCTCGTCGTC). The amplified products were visualized on 1% agarose gels. The signal was quantified using ImageJ software version 1.33u (NIH, Bethesda, MD, USA) and normalized to that of b-actin or GAPDH.
Creation of small interfering RNA approach to silence Src gene expression With the aim to diminish the expression of endogenous Src, L3.6pl and AsPC-1 cells as well as their 5-FU-resistant counterparts were transfected with a pool of Src siRNA using BLOCK-iT RNAi TOPO Transcription Kit and BLOCK-iT Dicer RNAi kit (both from Invitrogen GmbH) according to the manufacturer's instructions. The primer sequences used were as follows: Src si forward (TGCCTGCCTGCTGT TGGTCCTCTC) and Src si reverse (AAGCCCGCCTC CACTCTGAACTGC). Transfected cells were further assayed within 48 h. SiRNA based on LacZ gene was used as a control of off-target effects (primers and template were provided by the manufacturer).
Orthotopic pancreatic tumor model
AsPC 5-FU RES pancreatic cancer cells were injected into the pancreas of male athymic nu/nu Balb/c mice (Charles River Laboratories, Sulzfeld, Germany) as described earlier (Bruns et al., 1999) . Seven days after AsPC 5-FU RES cell implantation, mice were treated with 5-FU or vehicle control (equal volume of dimethyl sulfoxide). The Src kinase inhibitor PP2 was added in the combination therapy group 14 days after the beginning of treatment with 5-FU. The inhibition of tumor growth was monitored. After 4 weeks of treatment with PP2 (three times per week Â 1 mg/kg, intraperitoneally), 5-FU (two times per week Â 100 mg/kg, intraperitoneally) or the same doses of PP2 and 5-FU in combination was given, and necropsy was performed. The tumor volume was calculated using the formula V ¼ p/6 (a Â b Â c), where a, b and c represent the length, width and height of the mass.
Statistical analysis
Pancreatic tumor volume and weight were compared using the one-way analysis of variance test (Microcal Origin; Microcal Software, Northampton, MA, USA). The relative rates of liver and lymph node metastases were compared by Fisher's exact test (Systat Software Inc.). Statistical evaluation of in vitro studies was performed using the paired Student's t-test (Microcal Origin) with Po0.05 considered to be significant.
